@article{JTD29676,
author = {Yi Shi and Yi Huang and Tian-Tuo Zhang and Bin Cao and Hui Wang and Chao Zhuo and Feng Ye and Xin Su and Hong Fan and Jin-Fu Xu and Jing Zhang and Guo-Xiang Lai and Dan-Yang She and Xiang-Yan Zhang and Bei He and Li-Xian He and You-Ning Liu and Jie-Ming Qu and on behalf of Infection Study Group of Chinese Thoracic Society, Chinese Medical Association},
title = {Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {6},
year = {2019},
keywords = {},
abstract = {Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are the most common hospital-acquired infections in China. The difficulty in diagnosis and treatment of HAP/VAP leads to high mortality. In China, it has been nearly two decades since the initial “Guideline for the Diagnosis and Treatment of Hospital-acquired Pneumonia (draft)” was published in 1999 (1). Afterwards, a number of guidelines for HAP/VAP have been published or updated at home and abroad (2-10). The definitions of HAP/VAP have been changing as more and more relevant researches available highlighting greater details. Moreover, there are growing evidence in the epidemiology, etiology, clinical diagnosis and treatment of HAP/VAP, especially the accumulating evidence from the researches in China, which shows that the distribution and antibiotic resistance rate of HAP/VAP pathogens in China are largely different from the data reported in other countries. Therefore, it is necessary to amend the initial guideline in 1999 accordingly in order to better guide clinical practice.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/29676}
}